Search Results
Diese Website durchsuchen
548 Ergebnisse gefunden mit einer leeren Suche
- Pfizer signs Enodia Therapeutics research and licensing agreement worth more than $500 million for Sec61 protein degradation
Pfizer has entered a research and licensing collaboration with Enodia Therapeutics worth potentially more than $500 million to develop small-molecule therapies targeting protein synthesis through Sec61 inhibition. Enodia will discover and optimise small-molecule Sec61 inhibitors against multiple collaboration targets using its targeted protein degradation platform, while Pfizer will assume responsibility for subsequent clinical development, manufacturing, regulatory activities and commercialisation. The agreement includes an upfront payment, research funding, potential development and sales milestones and tiered royalties, positioning the partnership as a substantial investment in a differentiated protein-targeting approach. Field Content Article Type Deals Companies Pfizer; Enodia Therapeutics Deal Type Research collaboration and licensing agreement Potential Deal Value More than $500 million Upfront Payment Included; individual amount not disclosed Research Funding Included; amount not disclosed Milestone Payments Potential research, development and sales milestones Royalties Tiered royalties on future sales Technology/Modality Small-molecule Sec61 inhibition and targeted protein degradation Molecular Target Sec61 protein translocation complex Collaboration Scope Discovery and optimisation of small-molecule Sec61 inhibitors against multiple collaboration targets Enodia Responsibilities Research-stage discovery and optimisation of candidate inhibitors Pfizer Responsibilities Clinical development, manufacturing, regulatory activities and commercialisation following the research phase Development Stage Research and discovery Therapy Areas Not specified in the supplied announcement summary Geography Global collaboration What Happened Pfizer and Enodia Therapeutics signed a research and licensing agreement potentially worth more than $500 million focused on small-molecule Sec61 inhibitors. Why It Matters The collaboration provides external validation and substantial potential funding for Enodia's protein-targeting technology while expanding Pfizer's access to differentiated drug discovery approaches. Supporting Context Sec61 is involved in protein translocation during synthesis and represents a distinct intervention point for developing therapies against selected protein targets. Strategic Rationale Pfizer gains access to Enodia's specialised discovery platform while Enodia benefits from Pfizer's development and commercialisation capabilities. Potential Impact Successful research could generate new therapeutic candidates targeting proteins through inhibition of their synthesis and processing. Key Takeaway Pfizer has committed to a research and licensing partnership with Enodia carrying potential payments exceeding $500 million. What to Watch Disclosure of collaboration targets, research milestones, candidate nominations, development progression and milestone payments. Primary Source Enodia Therapeutics Relevant Date 13 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Horizon Space Acquisition signs $2 billion business combination agreement with ArcheNova Biotech
Horizon Space Acquisition I Corp. has agreed to combine with ArcheNova Biotech in a transaction valuing the clinical-stage biotechnology company at approximately $2 billion. The definitive business combination agreement, signed on 12 October and announced on 13 October, is intended to bring ArcheNova's extracellular vesicle and exosome-based therapeutic platforms into a publicly listed company. The proposed combined business is expected to seek a Nasdaq listing, subject to shareholder approvals, regulatory requirements and customary closing conditions. Field Content Article Type Deals Companies Horizon Space Acquisition I Corp.; ArcheNova Biotech Deal Type Definitive business combination agreement Transaction Structure Business combination involving a special purpose acquisition company and a clinical-stage biotechnology company Implied Company Valuation Approximately $2 billion Cash Consideration Not specified in the supplied announcement summary Transaction Status Definitive agreement signed; completion pending Agreement Date 12 October 2026 Announcement Date 13 October 2026 Target Company ArcheNova Biotech Technology/Modality Mesenchymal stromal cell-derived extracellular vesicles and exosome-based therapeutic platforms Development Stage Clinical-stage biotechnology Expected Listing Nasdaq, subject to transaction completion and applicable requirements Closing Conditions Required approvals and customary closing conditions Geography United States capital markets What Happened Horizon Space Acquisition I Corp. and ArcheNova Biotech entered a definitive business combination agreement valuing ArcheNova at approximately $2 billion. Why It Matters The proposed transaction could provide ArcheNova with access to public capital markets to support development of its extracellular vesicle and exosome-based therapeutic programmes. Supporting Context The $2 billion figure represents the proposed transaction valuation rather than a cash acquisition payment. Strategic Rationale The combination is intended to establish a publicly listed biotechnology company focused on ArcheNova's therapeutic technology platforms. Potential Impact Completion could expand ArcheNova's financing opportunities and public-market visibility, subject to the final transaction structure and available capital. Key Takeaway ArcheNova Biotech has agreed to a proposed $2 billion SPAC business combination with Horizon Space Acquisition I Corp. What to Watch Shareholder approvals, regulatory filings, transaction closing, final financing terms and the proposed Nasdaq listing. Primary Source Horizon Space Acquisition I Corp.; SEC filing Relevant Date 13 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- GSK expands AI drug discovery collaboration with Chai Discovery following successful laboratory evaluation
GSK has expanded its collaboration with Chai Discovery to apply AI-powered protein modelling and molecular design tools across pharmaceutical drug discovery following successful laboratory validation. The agreement gives GSK access to Chai Discovery's AI models for protein folding and molecular design, following laboratory evaluations that identified binders across all tested targets using designs generated without target-specific training. The collaboration strengthens GSK's AI-enabled discovery capabilities and demonstrates growing pharmaceutical interest in computational approaches that can generate experimentally validated molecular candidates. Field Content Article Type Deals Companies GSK; Chai Discovery Deal Type AI drug discovery collaboration Technology/Modality Artificial intelligence-based protein modelling and molecular design Platform Capabilities Protein folding prediction and molecular binder design Collaboration Scope Application of Chai Discovery's AI models to drug discovery activities within GSK's research pipeline Validation Results Laboratory testing identified binders across all evaluated targets using designs generated without target-specific training Financial Terms Not disclosed Development Stage Discovery and preclinical research Therapy Areas Not specified in the supplied announcement summary Geography International pharmaceutical research collaboration What Happened GSK entered a collaboration with Chai Discovery following successful laboratory evaluation of its AI-powered protein modelling and molecular design technology. Why It Matters The partnership provides further pharmaceutical validation of AI-generated molecular designs and could improve the efficiency of early-stage drug discovery. Supporting Context GSK's laboratory evaluation identified binders across all tested targets without target-specific model training. Strategic Rationale GSK gains access to specialised AI molecular design capabilities while Chai Discovery expands the pharmaceutical application of its technology. Potential Impact The collaboration could accelerate identification and optimisation of molecular candidates across selected drug discovery programmes. Key Takeaway GSK and Chai Discovery have established a substantive AI drug discovery collaboration supported by successful experimental validation. What to Watch Expansion into additional discovery programmes, disclosure of therapeutic targets, experimental validation results and advancement of AI-designed candidates. Primary Source Chai Discovery Relevant Date 9 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- China NMPA approves Foresee's Camcevi 42 mg six-month injection for advanced prostate cancer
China's NMPA has approved Foresee Pharmaceuticals' Camcevi 42 mg, a ready-to-use six-month leuprolide injection for adults with advanced prostate cancer. The approval authorises Camcevi (leuprolide mesylate) as a six-month subcutaneous depot injection in China, expanding the product's regulatory reach beyond existing approvals in the United States and Europe. Changchun GeneScience Pharmaceutical holds exclusive commercialisation rights in China, positioning the long-acting formulation as an additional treatment option for adults with advanced prostate cancer. Field Content Article Type Approvals Drug Name Camcevi Generic Name Leuprolide mesylate Company Foresee Pharmaceuticals Commercialisation Partner Changchun GeneScience Pharmaceutical Regulatory Authority China National Medical Products Administration (NMPA) Approval Type Marketing authorisation in China Indication Advanced prostate cancer Patient Population Adults with advanced prostate cancer Therapy Area Oncology; urology; prostate cancer Technology/Modality Ready-to-use long-acting subcutaneous depot formulation Drug Class Gonadotropin-releasing hormone (GnRH) agonist Approved Strength 42 mg Administration Subcutaneous injection every six months Dosing Frequency Once every six months Commercialisation Rights Changchun GeneScience Pharmaceutical holds exclusive commercialisation rights in China Geography China Existing Regulatory Footprint Previously approved in the United States and Europe What Happened China's NMPA approved Camcevi 42 mg for the treatment of adults with advanced prostate cancer. Why It Matters The approval expands access to a ready-to-use six-month leuprolide depot formulation in China and extends Camcevi's international regulatory footprint. Supporting Context Camcevi is a long-acting leuprolide mesylate formulation administered by subcutaneous injection every six months. Potential Impact The approval could broaden treatment options for eligible patients with advanced prostate cancer while reducing injection frequency to twice yearly. Key Takeaway Foresee Pharmaceuticals has secured Chinese marketing authorisation for Camcevi 42 mg, with Changchun GeneScience Pharmaceutical responsible for commercialisation in China. What to Watch Commercial launch timing in China, pricing and reimbursement, physician adoption, market access and future geographic expansion. Primary Source Foresee Pharmaceuticals Relevant Date 12 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves Hovilpri as novel oral treatment for refractory herpes simplex infections in immunocompromised adults
The FDA has approved Hovilpri, a novel oral helicase-primase inhibitor for refractory mucocutaneous herpes simplex virus infections in immunocompromised adults. Hovilpri (pritelivir), developed by AiCuris and associated with Asahi Kasei Therapeutics, is approved for patients whose mucocutaneous HSV lesions are refractory to acyclovir, valacyclovir or famciclovir. The approval introduces a new antiviral mechanism for a difficult-to-treat infection, representing the first FDA-approved treatment with a novel mechanism for this condition in nearly three decades. Field Content Article Type Approvals Drug Name Hovilpri Generic Name Pritelivir Companies AiCuris; Asahi Kasei Therapeutics Regulatory Authority U.S. Food and Drug Administration Approval Type New drug approval Indication Refractory mucocutaneous herpes simplex virus infections Patient Population Immunocompromised adults with mucocutaneous HSV lesions refractory to acyclovir, valacyclovir or famciclovir Therapy Area Infectious diseases; virology Technology/Modality Oral helicase-primase inhibitor Administration Oral Target Pathogen Herpes simplex virus Refractory Treatment Criteria Resistance or inadequate response to acyclovir, valacyclovir or famciclovir as described in the approval announcement Mechanism of Action Inhibition of the viral helicase-primase complex involved in HSV DNA replication Geography United States What Happened The FDA approved Hovilpri for immunocompromised adults with refractory mucocutaneous herpes simplex virus infections. Why It Matters The approval provides a novel antiviral mechanism for patients with limited treatment options following failure of established HSV therapies. Supporting Context Hovilpri represents the first FDA-approved treatment with a new mechanism for this condition in nearly 30 years. Potential Impact The oral therapy could expand treatment options for immunocompromised adults with difficult-to-treat mucocutaneous HSV infections. Key Takeaway Hovilpri introduces a new FDA-approved oral antiviral option for refractory HSV infections in immunocompromised adults. What to Watch US commercial availability, prescribing guidance, clinical adoption, reimbursement and real-world effectiveness in refractory HSV infections. Primary Source Asahi Kasei Therapeutics Relevant Date 9 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves Teva's Weltruza as first once-monthly subcutaneous olanzapine injection for schizophrenia
Teva has secured FDA approval for Weltruza, the first once-monthly subcutaneous extended-release olanzapine injection for adults with schizophrenia. The approval is supported by the Phase III SOLARIS trial, which demonstrated improvements in schizophrenia symptoms, overall illness severity and personal and social functioning. Weltruza requires no loading doses, oral supplementation or post-injection monitoring, offering a differentiated long-acting treatment option for adults living with schizophrenia. Field Content Article Type Approvals Drug Name Weltruza Generic Name Olanzapine Company Teva Pharmaceuticals Regulatory Authority U.S. Food and Drug Administration Approval Type New long-acting injectable formulation approval Indication Schizophrenia Patient Population Adults with schizophrenia Therapy Area Psychiatry; mental health Technology/Modality Once-monthly subcutaneous extended-release injectable antipsychotic Administration Subcutaneous injection once monthly Clinical Study Phase III SOLARIS Key Clinical Findings Improvements in schizophrenia symptoms, illness severity and personal and social functioning Treatment Requirements No loading doses, oral supplementation or post-injection monitoring required Geography United States What Happened The FDA approved Weltruza as the first once-monthly subcutaneous extended-release olanzapine injection for adults with schizophrenia. Why It Matters The approval introduces a differentiated long-acting olanzapine formulation that may simplify treatment administration and reduce monitoring burdens compared with other injectable olanzapine approaches. Supporting Context The Phase III SOLARIS trial demonstrated improvements across schizophrenia symptom severity and functional outcomes. Potential Impact A once-monthly treatment without oral supplementation or post-injection monitoring requirements could offer greater flexibility for eligible patients and healthcare providers. Key Takeaway Teva has received FDA approval for the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia. What to Watch US commercial launch, prescribing uptake, payer coverage, clinical adoption and real-world treatment persistence. Primary Source Teva Pharmaceuticals Relevant Date 9 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Biohaven licenses IgG degrader portfolio to Ono Pharma in Asian agreement worth up to $100m in near-term payments
Biohaven grants Ono Pharma regional rights to BHV-1300 and extracellular IgG degrader programmes Biohaven has entered a licensing agreement granting Ono Pharmaceutical rights to its extracellular IgG degrader programmes in Japan and selected Asian markets, including Phase 3 candidate BHV-1300. The agreement includes an $80m upfront payment, a potential additional $20m milestone and royalties of approximately 20%, expanding the regional commercial opportunity for Biohaven's immunology portfolio. Field Content Alert Type Deals Companies Biohaven; Ono Pharmaceutical Deal Type Exclusive regional licensing agreement Asset or Company BHV-1300 and follow-on extracellular IgG degrader programmes Therapy Area(s) Immunology; autoimmune diseases; Graves' disease Technology or Modality Extracellular IgG degradation Deal Value $80m upfront; potential additional $20m milestone; approximately 20% royalties Development Stage (if relevant) BHV-1300 in Phase 3 development for Graves' disease Geography Japan and selected Asian markets What Happened Biohaven entered a strategic licensing agreement with Ono Pharmaceutical covering BHV-1300 and follow-on extracellular IgG degrader programmes in specified Asian territories. Why It Matters The agreement provides Biohaven with near-term funding and a regional development and commercialisation partner for its extracellular IgG degradation platform. Supporting Context BHV-1300 is an investigational extracellular IgG degrader being evaluated in Phase 3 clinical development for Graves' disease. Strategic Rationale (optional) Ono gains regional access to Biohaven's investigational IgG degradation technology while Biohaven retains opportunities outside the licensed territories. Potential Impact (optional) The partnership could support future development and commercial access to IgG degrader treatments in the licensed Asian markets, subject to successful trials and regulatory approvals. Key Takeaway Biohaven's agreement with Ono combines $80m upfront funding with additional milestone and royalty opportunities for its IgG degrader portfolio. What to Watch (optional) BHV-1300 Phase 3 results, regulatory submissions and regional development milestones. Primary Source https://ir.biohaven.com/news-releases/news-release-details/biohaven-enters-strategic-licensing-agreement-ono-pharma Relevant Date 8 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Roche partners with Defand Therapeutics to discover molecular glue drugs for cancer and immune diseases
Roche and Defand enter molecular glue discovery collaboration targeting cancer and immune-mediated diseases Roche has entered a drug-discovery collaboration with China-based Defand Therapeutics focused on developing molecular glue medicines for oncology and immune-mediated diseases. The agreement highlights growing pharmaceutical interest in targeted protein degradation and Chinese biotechnology innovation, although the companies have not publicly confirmed the financial terms. Field Content Alert Type Deals Companies Roche; Defand Therapeutics Deal Type Research and drug-discovery collaboration Asset or Company Molecular glue drug-discovery programmes Therapy Area(s) Oncology; immune-mediated diseases Technology or Modality Molecular glue therapeutics; targeted protein degradation Deal Value Financial terms not publicly disclosed; reported potential value approaching $1bn remains unconfirmed Development Stage (if relevant) Discovery and research Geography Switzerland; China What Happened Roche and Defand Therapeutics entered a collaboration to discover and develop molecular glue medicines targeting cancer and immune-mediated diseases. Why It Matters The agreement demonstrates pharmaceutical interest in molecular glue technology and the growing role of Chinese biotechnology companies in international drug-discovery partnerships. Supporting Context Molecular glues are small molecules designed to promote interactions between proteins, potentially enabling the degradation of disease-associated targets. Strategic Rationale (optional) The collaboration provides Roche with access to Defand's molecular glue discovery capabilities while supporting the international development of Defand's technology. Potential Impact (optional) Successful research could generate drug candidates against disease-associated proteins that have historically been difficult to target. Key Takeaway Roche's collaboration with Defand adds to pharmaceutical investment in molecular glue drug discovery and cross-border biotechnology partnerships. What to Watch (optional) Further disclosure of financial terms, nominated drug candidates and progression into preclinical development. Primary Source https://www.statnews.com/2026/10/08/roche-defand-therapeutics-drug-development-deal/ Relevant Date 8 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- ABIONYX Pharma and OLON partner to prepare CER-001 for regulatory approval and commercial manufacturing
ABIONYX Pharma and OLON have established a strategic manufacturing partnership to support regulatory preparations and potential commercial production of CER-001. The agreement covers an integrated manufacturing framework for CER-001, a recombinant apoA-I-based HDL-mimetic biologic, including two validation batches supporting its LCAT deficiency regulatory pathway. The collaboration also prepares for potential commercial manufacturing in sepsis, strengthening the production infrastructure needed for future regulatory and commercial milestones. Field Content Article Type Deals Companies ABIONYX Pharma; OLON Deal Type Strategic biologics manufacturing partnership Key Asset CER-001 Therapy Areas LCAT deficiency; sepsis Technology/Modality Recombinant apolipoprotein A-I-based HDL-mimetic biologic Manufacturing Scope Integrated manufacturing framework supporting regulatory validation and potential commercial production Validation Activities Two validation batches Regulatory Focus LCAT deficiency regulatory pathway Commercial Manufacturing Focus Potential future commercial production for sepsis Financial Terms Not disclosed in the supplied announcement summary What Happened ABIONYX Pharma and OLON entered a strategic manufacturing partnership to advance production readiness for CER-001. Why It Matters The agreement supports manufacturing validation and regulatory preparation for a specialist biologic while establishing infrastructure for potential commercial supply. Supporting Context CER-001 is a recombinant apoA-I-based HDL-mimetic biologic being developed in LCAT deficiency and sepsis. Strategic Rationale ABIONYX is strengthening CER-001 manufacturing capabilities through OLON's biologics production expertise to support regulatory requirements and future scale-up. Potential Impact The collaboration could improve manufacturing readiness and support future regulatory submissions and commercial supply if development programmes succeed. Key Takeaway ABIONYX and OLON have partnered to support CER-001 validation manufacturing and potential commercial production. What to Watch Completion of validation batches, regulatory progress in LCAT deficiency, sepsis development milestones and commercial manufacturing readiness. Primary Source ABIONYX Pharma Relevant Date 7 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves Tukysa combination as first-line maintenance therapy for HER2-positive advanced breast cancer
The FDA has approved Pfizer's Tukysa in combination with trastuzumab and pertuzumab as a first-line maintenance treatment for adults with HER2-positive advanced breast cancer. The approval covers adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment and is supported by the Phase III HER2CLIMB-05 trial involving 654 patients. The decision introduces an additional targeted maintenance treatment option for patients with advanced HER2-positive disease and expands the clinical role of tucatinib. Field Content Article Type Approvals Drug Name Tukysa Generic Name Tucatinib Company Pfizer Regulatory Authority U.S. Food and Drug Administration Approval Type Expanded indication for first-line maintenance treatment Indication Unresectable locally advanced or metastatic HER2-positive breast cancer Patient Population Adults with HER2-positive advanced breast cancer following induction treatment Approved Regimen Tucatinib plus trastuzumab and pertuzumab Therapy Area Oncology; breast cancer Technology/Modality Oral HER2-targeted tyrosine kinase inhibitor combined with HER2-directed monoclonal antibodies Clinical Study Phase III HER2CLIMB-05 Study Population 654 patients Treatment Setting First-line maintenance following induction treatment Geography United States What Happened The FDA approved tucatinib in combination with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer. Why It Matters The approval adds a targeted maintenance option in the first-line treatment pathway for advanced HER2-positive breast cancer. Supporting Context The approval is supported by the Phase III HER2CLIMB-05 trial involving 654 patients. Potential Impact The regimen could broaden treatment choices for eligible patients requiring continued HER2-directed therapy after induction treatment. Key Takeaway Pfizer's Tukysa combination has received FDA approval for first-line maintenance treatment of advanced HER2-positive breast cancer. What to Watch Clinical adoption, treatment sequencing, updated oncology guidelines and real-world outcomes following the approval. Primary Source U.S. Food and Drug Administration Relevant Date 7 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Asieris and Theramex sign licensing agreement for cervical precancer therapy Cevira
Asieris and Theramex have entered a licensing agreement for Cevira, a treatment platform targeting cervical precancerous lesions. The agreement brings together Asieris and Theramex around the development and commercialisation potential of Cevira in women's health, although the supplied report does not establish the precise territorial rights. The partnership could support future market access for Cevira, with financial terms and detailed commercial responsibilities remaining unconfirmed in the available summary. Field Content Article Type Deals Companies Asieris; Theramex Deal Type Pharmaceutical licensing agreement Key Asset Cevira Therapy Areas Women's health; cervical precancerous lesions Technology/Modality Cervical precancer treatment platform Licensed Territories Not confirmed in the supplied source summary Financial Terms Not confirmed in the supplied source summary Development Responsibilities Not specified in the supplied source summary Commercial Responsibilities Not specified in the supplied source summary What Happened Asieris and Theramex entered a licensing agreement concerning Cevira for cervical precancerous lesions. Why It Matters The agreement establishes a commercial partnership around a women's health treatment platform addressing cervical precancerous disease. Supporting Context Cevira is being developed as a treatment approach for cervical precancerous lesions; detailed agreement terms were not available in the supplied editorial summary. Strategic Rationale The partnership is intended to support Cevira's development and commercialisation opportunities through collaboration between Asieris and Theramex. Potential Impact The agreement could contribute to broader future access to Cevira if applicable regulatory and commercial milestones are achieved. Key Takeaway Asieris and Theramex have signed a licensing agreement for Cevira, with financial and territorial terms requiring confirmation. What to Watch Confirmation of licensed territories, financial terms, development responsibilities, regulatory milestones and commercial launch plans. Primary Source The Pharma Letter Relevant Date 7 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves Novartis Rhapsido as first treatment for symptomatic dermographism
Novartis has secured FDA approval for Rhapsido as the first treatment specifically approved for symptomatic dermographism in adults inadequately controlled by H1 antihistamines. Rhapsido (remibrutinib) is an oral selective BTK inhibitor whose expanded indication is supported by the Phase III RemIND trial, in which approximately twice as many treated adults achieved complete hive resolution at Week 12 compared with placebo. The decision extends Rhapsido beyond chronic spontaneous urticaria into symptomatic dermographism, a form of chronic inducible urticaria. Field Content Article Type Approvals Drug Name Rhapsido Generic Name Remibrutinib Company Novartis Regulatory Authority U.S. Food and Drug Administration Approval Type Expanded indication; first approved treatment for symptomatic dermographism Indication Symptomatic dermographism Patient Population Adults with symptomatic dermographism inadequately controlled by H1 antihistamines Therapy Area Dermatology; immunology; chronic inducible urticaria Technology/Modality Oral selective Bruton's tyrosine kinase inhibitor Clinical Study Phase III RemIND Key Clinical Finding Approximately twice as many Rhapsido-treated adults achieved complete hive resolution at Week 12 compared with placebo Previous Indication Chronic spontaneous urticaria New Indication Symptomatic dermographism Geography United States What Happened The FDA approved Rhapsido for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Why It Matters The decision establishes the first specifically approved treatment for symptomatic dermographism and introduces an oral targeted therapy for eligible patients. Supporting Context The Phase III RemIND study demonstrated improved complete hive resolution at Week 12 compared with placebo. Potential Impact The expanded indication could provide a new treatment option for adults whose symptoms remain inadequately controlled with antihistamines. Key Takeaway Novartis has secured a first-of-its-kind FDA approval for Rhapsido in symptomatic dermographism. What to Watch US commercial rollout, treatment guideline updates, clinician adoption and longer-term real-world effectiveness and safety. Primary Source Novartis Relevant Date 7 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

